Randomized Phase III Trial of Herceptin Followed by Chemotherapy Plus Herceptin Versus the Combination of Herceptin and Chemotherapy as Palliative Treatment in Patients With HER2-Overexpressing Advanced/Metastatic Breast Cancer

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 20 Apr 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Trastuzumab (Primary) ; Paclitaxel
Indications Advanced breast cancer; Carcinoma; HER2 positive breast cancer
Focus Therapeutic Use

Most Recent Events

10 Dec 2022 Results of safety analysis after 11 years of follow-up, presented at the 45th Annual San Antonio Breast Cancer Symposium
10 Jul 2018 Planned End Date changed from 1 Jun 2018 to 1 Jul 2024.
19 Dec 2016 Results published in the Annals of Oncology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight